# Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)

> **NCT00844142** · PHASE2 · UNKNOWN · sponsor: **Charite University, Berlin, Germany** · enrollment: 80 (estimated)

## Conditions studied

- Moderate to Severe Active Axial Spondyloarthritis

## Interventions

- **DRUG:** Etanercept 25mg
- **DRUG:** Sulfasalazine

## Key facts

- **NCT ID:** NCT00844142
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-11
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2009-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00844142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00844142, "Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00844142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*